CA-NODLE
19.11.2021 16:02:10 CET | Business Wire | Press release
Nodle, one of the world’s largest ecosystems of connected devices, today announced their entrance into Polkadot’s inaugural parachain slot auction and crowdloan. Nodle provides infrastructure, software, and data access to the Internet of Things (IoTs) using Bluetooth Low Energy (BLE) on existing smartphones. Polkadot is a blockchain ecosystem that recently opened for developers to register their projects on their parachains, enabling access to its strong native userbase and interoperability with other blockchains—like Ethereum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211119005287/en/
Nodle expects that achieving a parachain will dramatically empower its next-generation IoT capabilities around connectivity, machine-to-machine payments, air-quality monitoring, asset tracking, a way to authenticate and secure devices, and more. This also should enable all other chain ecosystems which are interoperable with Polkadot to benefit from Nodle’s vast network—including the millions of nodes connecting to up to 30 million IoT devices and sensors every day.
When anyone contributes to the Nodle parachain crowdloan by locking their Polkadot tokens (DOT), they will receive NODL rewards from an allocated pool of 850 million NODL — that’s 23% of the total Nodle reserves or 10% of Nodle Mainnet. After two years, all DOT contributions will be automatically returned to the contributors, in addition to the Nodle token (NODL) rewards they will earn. To receive all of the details and participate, visit Nodle’s Parachain webpage here: https://parachain.nodle.com
“Nodle is thrilled to join the Polkadot parachain movement, which we believe is at the forefront of Web 3.0 and blockchain innovation,” said Nodle Chief Blockchain Officer, Eliott Teissonniere. “Our robust IoT network will join ranks with other systems for secure, symbiotic relationships. Nodle will supply its revolutionary decentralized network technology, while seeking new product frontiers, by building products with other parachain DeFi products like decentralized exchanges (DEXs), smart contract platforms, decentralized identity solutions, and bridges to other networks.”
“Nodle is making its Decentralized Wireless (DeWi) network and apps composable with many services from other chains, and having a parachain will provide us with a way to make this interoperability a reality,” said Nodle CEO and Founder Micha Benoliel. “Nodle conducted interoperability tests with other parachains, like the Acala Network, earlier this year so we understand the power of this opportunity. Achieving a Polkadot parachain represents the expansion of our Web 3.0 ambitions and will accelerate how the Nodle network interacts with the entire Polkadot blockchain ecosystem.”
About Nodle
Nodle is a decentralized IoT (Internet of Things) network on Polkadot providing secure, low-cost connectivity, and data liquidity to connect billions of IoT devices worldwide. The Nodle network is powered by millions of Bluetooth-enabled smartphones that earn Nodle Cash (NODL). Nodle’s powerful IoT stack allows multiple uses including connecting and securing physical assets, tracking lost or valuable items, capturing sensor data, and authenticating security certificates. Nodle provides insights for consumer electronics manufacturers, enterprises, smart cities, the finance industry and more. Since its creation in 2017, Nodle has become one of the world’s largest wireless networks by number of base stations. Join #TheCitizenNetwork by downloading the Nodle Cash app for iOS or Android .
Twitter | Telegram | Discord | YouTube | Wiki | GitHub | Website
View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005287/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom